ESPN/ERA-EDTA Registry and ERA-EDTA Registry, Amsterdam, the Netherlands.
Division of Pediatric Nephrology, University of Heidelberg, Center for Pediatrics and Adolescent Medicine, Heidelberg, Germany.
Kidney Int. 2016 Jun;89(6):1355-62. doi: 10.1016/j.kint.2016.02.016. Epub 2016 Apr 13.
We aimed to describe survival in European pediatric dialysis patients and compare the differential mortality risk between patients starting on hemodialysis (HD) and peritoneal dialysis (PD). Data for 6473 patients under 19 years of age or younger were extracted from the European Society of Pediatric Nephrology, the European Renal Association, and European Dialysis and Transplant Association Registry for 36 countries for the years 2000 through 2013. Hazard ratios (HRs) were adjusted for age at start of dialysis, sex, primary renal disease, and country. A secondary analysis was performed on a propensity score-matched (PSM) cohort. The overall 5-year survival rate in European children starting on dialysis was 89.5% (95% confidence interval [CI] 87.7%-91.0%). The mortality rate was 28.0 deaths per 1000 patient years overall. This was highest (36.0/1000) during the first year of dialysis and in the 0- to 5-year age group (49.4/1000). Cardiovascular events (18.3%) and infections (17.0%) were the main causes of death. Children selected to start on HD had an increased mortality risk compared with those on PD (adjusted HR 1.39, 95% CI 1.06-1.82, PSM HR 1.46, 95% CI 1.06-2.00), especially during the first year of dialysis (HD/PD adjusted HR 1.70, 95% CI 1.22-2.38, PSM HR 1.79, 95% CI 1.20-2.66), when starting at older than 5 years of age (HD/PD: adjusted HR 1.58, 95% CI 1.03-2.43, PSM HR 1.87, 95% CI 1.17-2.98) and when children have been seen by a nephrologist for only a short time before starting dialysis (HD/PD adjusted HR 6.55, 95% CI 2.35-18.28, PSM HR 2.93, 95% CI 1.04-8.23). Because unmeasured case-mix differences and selection bias may explain the higher mortality risk in the HD population, these results should be interpreted with caution.
我们旨在描述欧洲儿科透析患者的生存情况,并比较开始血液透析 (HD) 和腹膜透析 (PD) 的患者之间的差异死亡率风险。从欧洲儿科学会、欧洲肾脏协会和欧洲透析与移植协会 36 个国家的登记处提取了 2000 年至 2013 年 6473 名 19 岁以下患者的数据。调整了起始透析时的年龄、性别、原发性肾脏疾病和国家的风险比 (HR)。对倾向评分匹配 (PSM) 队列进行了二次分析。在开始透析的欧洲儿童中,总体 5 年生存率为 89.5%(95%置信区间 [CI] 87.7%-91.0%)。总的死亡率为每 1000 患者年 28.0 例死亡。这在透析的第一年最高(36.0/1000),在 0-5 岁年龄组最高(49.4/1000)。心血管事件(18.3%)和感染(17.0%)是主要的死亡原因。与 PD 相比,选择开始 HD 的儿童死亡率风险更高(调整后的 HR 1.39,95%CI 1.06-1.82,PSM HR 1.46,95%CI 1.06-2.00),尤其是在透析的第一年(HD/PD 调整后的 HR 1.70,95%CI 1.22-2.38,PSM HR 1.79,95%CI 1.20-2.66),当开始时年龄大于 5 岁(HD/PD:调整后的 HR 1.58,95%CI 1.03-2.43,PSM HR 1.87,95%CI 1.17-2.98),并且儿童在开始透析之前仅由肾病医生进行了很短时间的治疗(HD/PD 调整后的 HR 6.55,95%CI 2.35-18.28,PSM HR 2.93,95%CI 1.04-8.23)。由于未测量的病例混杂差异和选择偏倚可能解释了 HD 人群中更高的死亡率风险,因此应谨慎解释这些结果。